Future Oncology

Article	Citations
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancer	121
The SYK inhibitor: a novel agent for improved outcomes in relapsed/refractory diffuse large B-cell lymphoma	81
Brain Injury after Cranial Radiotherapy Combined with Immunotherapy for Brain Metastases in Lung Cancer: A Retrospective Study	76
ToPCourT protocol: a phase II trial of Trilaciclib, Pembrolizumab, gemcitabine, and Carboplatin in locally advanced/unresectable or metastatic Triple-negative breast cancer	63
Phase II basket study of brigatinib for ALK fusion-positive solid tumors: WJOG15221M/ALLBREAK (a decentralized clinical trial design)	62
Immunotherapy for Liposarcoma: Emerging Opportunities and Challenges	57
Radiofrequency ablation versus stereotactic body radiation therapy for hepatocellular carcinoma: a meta-regression	57
A Multicenter, Phase Ib/II, Open-Label Study of Tivozanib with Durvalumab in Advanced Hepatocellular Carcinoma (DEDUCTIVE)	57
The relationship between VDR polymorphisms and keratinocyte carcinomas: a systematic review and meta-analysis	57
RELAY: safety and efficacy of ramucirumab plus erlotinib in elderly Japanese patients with metastatic EGFR -mutated NSCLC	54
Treatment patterns and clinical outcomes in metastatic urothelial carcinoma: a German retrospective real-world analysis	54
How enfortumab vedotin plus pembrolizumab affects the quality of life of people with advanced urothelial cancer compared with platinum-based chemotherapy: a plain language summary of patient-reported	51
Should One Use the Combination of Abiraterone and Poly(ADP-ribose) Polymerase Inhibitors as First-Line Therapy for all Patients with Metastatic Castration-Resistant Prostate Cancer?	50
Results of a survey study on health professionals’ perceptions of tumor boards in Brazil	40
Diagnosis of chondrosarcoma in a noninvasive way using volatile organic compounds in exhaled breath: a pilot study	39
Sex bias phenomenon in oral cancer: an insight	38
The prognostic value of radiomic features in liver-limited metastatic colorectal cancer patients from the TRIBE2 study	38
In -Class Transition from Bortezomib-Based Therapy to IRd is an Effective Approach in Newly Diagnosed Multiple Myeloma	37
Systematic literature review of the epidemiology of neurotrophic tyrosine receptor kinase positive solid tumor sites	36
Prevalence of homologous recombination biomarkers in multiple tumor types: an observational study	35
Real-world outcomes in non-small-cell lung cancer patients with MET Exon 14 skipping mutation and brain metastases treated with capmatinib	34
Impact of social determinants of health on treatment patterns and outcomes in multiple myeloma	33
Cost–effectiveness of aumolertinib as first-line treatment for EGFR-mutated advanced nonsmall-cell lung cancer	33
Matching-adjusted indirect comparison of selpercatinib and pralsetinib in RET fusion–positive non–small cell lung cancer	33
Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304)	33

Molecular preselection of pediatric patients with solid tumors treated with tyrosine kinase inhibitors	32
Trastuzumab deruxtecan in HER2-mutant metastatic non-small-cell lung cancer: a plain language summary of the DESTINY-Lung02 study	32
Sacituzumab Govitecan: Past, Present and Future of a New Antibody–Drug Conjugate and Future Horizon	32
Barriers and solutions for healthcare professionals to involve patients as partners in oncology research: Project RISE	32
Correction	31
Real-world treatment patterns and genetic testing in a metastatic castration-resistant prostate cancer setting in Europe	31
Evaluation of surgical treatment outcomes and development of a prognostic model for patients with small cell lung cancer	31
Crosstalk Between Circrnas and the PI3K/AKT and/or MEK/ERK Signaling Pathways in Digestive Tract Malignancy Progression	31
Randomized phase II study comparing neoadjuvant 5-fluorouracil/oxaliplatin/docetaxel versus docetaxel/oxaliplatin/S-1 for patients with type 4 or large type 3 gastric cancer	30
Odronextamab in people with relapsed or refractory follicular lymphoma: plain language summary of the ELM-2 study	30
The ‘Hit-and-Run’ Strategy and Viral Carcinogenesis	29
Plain language summary: 5-year results from the CROWN study of lorlatinib vs crizotinib in non-small-cell lung cancer	27
Number needed to treat to avoid progression and death and cost analysis: zanubrutinib versus acalabrutinib in relapsed/refractory chronic lymphocytic leukemia	27
Comparison of tumor-agnostic and tumor-specific clinical oncology trial designs: a systematic review and meta-analysis	26
Real-world results of first-line immunotherapy or targeted therapy for metastatic melanoma in Finland: a cohort study	25
MISTOSUS: a phase II trial of Viscum album extract adjuvant therapy for relapsed resectable osteosarcoma	25
Indirect treatment comparisons of momelotinib vs pacritinib safety and anemia outcomes in patients with myelofibrosis	25
Prolonging the lives of African–Americans with metastatic breast cancer by adding palbociclib to an aromatase inhibitor in routine clinical practice: a plain language summary of a real-world database	25
Selinexor plus ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis: SENTRY Phase 3 study design	25
Efficacy and safety of immune checkpoint inhibitors combined with recombinant human endostatin and chemotherapy as the first-line treatment of advanced non-small-cell lung cancer	24
Association of exosomal miR17-92a cluster and target genes with breast cancer risk	24
DOMENICA: dostarlimab versus chemotherapy alone in first-line MMR-deficient advanced endometrial cancer patients	23
Plain language summary of TASUKI-52: A study looking at nivolumab plus platinum chemotherapy and bevacizumab as a combined treatment for people with advanced or recurrent nonsquamous non-small cell lu	23
Safety and efficacy of anlotinib hydrochloride capsules in advanced non-small-cell lung cancer: a multicenter, real-world study	23
A Multicenter Randomized, Controlled Clinical Trial of Adjuvant Sintilimab for Esophageal Squamous Cell Carcinoma	23
Combination niraparib and abiraterone for HRR-altered metastatic castration-resistant prostate cancer	23
Association Between Event-Free Survival and Overall Survival in Early-Stage Triple-Negative Breast Cancer	22
Can we predict the progression of premalignant pancreatic cystic tumors to ductal adenocarcinoma?	22
A plain language summary of the molecular changes in the tumors of people with BRAF V600E–mutant colorectal cancer in the BEACON study	21
The first United Arab Emirates expert consensus recommendations for the diagnosis and management of early and advanced non-small cell lung cancer	21
Avelumab real-world use in advanced Merkel cell carcinoma: a systematic review and non-comparative meta-analysis	21
BREAKWATER Phase III: results for encorafenib and cetuximab plus mFOLFOX6 in first-line BRAF V600E–mutant metastatic colorectal cancer	20
A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3)	20
Overcoming Immunosuppression and Pro-Tumor Inflammation in Lung Cancer with Combined IL-1β and PD-1 Inhibition	20
Autologous Cell Immunotherapy (IGV-001) with IGF-1R Antisense Oligonucleotide in Newly Diagnosed Glioblastoma Patients	19
An MMP-based risk score strongly distinguishes prognosis in hepatocellular carcinoma after resection	19
Patient preferences for adjuvant therapy in renal cell carcinoma: a discrete-choice experiment	19
Plain language summary of the development of tepotinib: a treatment for a subtype of non-small cell lung cancer called MET exon 14 skipping	18
ELAINE 3: phase 3 study of lasofoxifene plus abemaciclib to treat ER+/HER2-, ESR1 -mutated, metastatic breast cancer	18
REGAL: galinpepimut-S vs. best available therapy as maintenance therapy for acute myeloid leukemia in second remission	18
Impact of radiation dose to immune cells on survival in patients with extensive-stage small cell lung cancer receiving consolidative thoracic radiotherapy after chemoimmunotherapy	17
Treatment intensification in metastatic castration-sensitive prostate cancer: a real-world study in Alberta, Canada	17
Social media for healthcare professionals in oncology: results from a cross-sectional survey conducted across eight countries in Asia, Latin America, and the Middle East	17
Association of Epstein–Barr virus DNA and SAA with S1 maintenance therapy outcomes in patients with metastatic nasopharyngeal carcinoma	17
Correction	17
Real-world application of next-generation sequencing-based test for surgically resectable colorectal cancer in clinical practice	16
Application and Prospect of Single-Cell Sequencing in Cancer Metastasis	16
Tetra-modality bladder preservation with avelumab for muscle-invasive urothelial cancer: a phase II trial (TRIUMPH-B01)	16
Lorlatinib as a treatment for ALK-positive lung cancer	15
Effect of preoperative peripheral blood platelet volume index on prognosis in patients with invasive breast cancer	15

Potential value of tumor stiffness and sE-cadherin in predicting the response to neoadjuvant therapy in HER2-positive breast cancers	15
Chemotherapy-free treatment with acalabrutinib can benefit patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who were never treated before: a plain language summary of the ELEVATE-	15
Real-world Evidence of Multiple Myeloma Treated from 2013 to 2019 in the Hospital District of Helsinki and Uusimaa, Finland	15
Patient characteristics, treatment patterns, and clinical outcomes in HER2-negative early breast cancer by germline BRCA status	15
Real-world post-2020 first-line maintenance treatment patterns in patients with advanced ovarian cancer in the US	15
A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an in situ vaccine for cisplatin-ineligible MIBC: the RAD VACCINE MIBC tri	15
Design and rationale of the phase II PANDORA trial: first line chemo-immunotherapy in advanced Merkel cell carcinoma	14
Characteristics and outcomes of patients with HCC treated with atezolizumab/bevacizumab, stratified by second line therapy	14
Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer: a plain language summary of the DESTINY-Lung01 study	14
The Benefit of Immunotherapy in Patients with Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis	14
Real-world adjuvant chemotherapy patterns and outcomes among elderly patients with resected early non-small-cell lung cancer in the USA	14
As a Potential Predictor of Pan-Cancer, UBE2S is Related to Tumor-Associated Macrophage Infiltration	14
Preferences for First-Line Treatment of Advanced Urothelial Carcinoma among US Practicing Oncologists and Patients	14
Relationship Between Nurses’ Perceptions and Financial Toxicity Management in the Public Health Insurance System	14
Association of human papillomavirus with breast cancer: a new perspective on an old debate	14
Multimodal Analysis of ctDNA Methylation and Fragmentomic Profiles Enhances Detection of Nonmetastatic Colorectal Cancer	14
LITESPARK-012: Pembrolizumab Plus Lenvatinib With or Without Belzutifan or Quavonlimab for Advanced Renal Cell Carcinoma	14
Response to letter to editor on the article: Ge W, Chen C, Wu N et al. Hedgehog pathway inhibitor real-world treatment patterns in patients with basal cell carcinoma: a	14
MDX-2001–101 study protocol: a phase I/IIa, multicenter, first-in-human, open-label clinical trial evaluating MDX2001 monotherapy in patients with advanced solid tumors	14
Disease management landscape in patients with mantle cell lymphoma in Japan: a real-world study	14
Co-expression of CD44v6 and MMP2 predicts lung metastasis and unfavorable prognosis in osteosarcoma	13
Ponatinib in the treatment of acute lymphoblastic leukemia	13
Nomogram to predict overall survival in patients with primary bladder neuroendocrine carcinoma: a population-based study	13
Thyroid cancers reveal significant age- and gender-specific associations in papillary, medullary, and multinodularity types in Ha’il, Saudi Arabia: retrospective analysis	13
Exploring the Connection Between Microsatellite Instability and Inflammatory Indicators in Cancers	13
Plain language summary of a clinical study: anamorelin for treatment of Japanese people with non-small cell lung cancer and cachexia	13
Metabolic syndrome and symptom burden in allogeneic hematopoietic stem cell transplantation survivors	13
Outdoor air pollution and oral cancer: critical viewpoints and future prospects	13
Plain language summary and patient perspective of the revised STARS study: long-term results of a study that compared the effectiveness of radiotherapy to surgery in people with non-small-cell lung ca	13
Indirect treatment comparison of momelotinib vs fedratinib safety in patients with myelofibrosis	12
Is there a best JAK inhibitor in myelofibrosis when it comes to safety and anemia outcomes?	12
Real-world evidence in lung and hematologic oncology health technology appraisals: a review of six assessment agencies	12
Deep learning-based multiomics integration model for predicting axillary lymph node metastasis in breast cancer	12
Interstitial lung disease recurrence on chemotherapy rechallenge in breast cancer: a nationwide Japanese database	12
Pediatric oncohematological exercise program in hospital: clinical trial study protocol	12
Revolutionizing colorectal cancer treatment: unleashing the potential of miRNAs in targeting cancer stem cells	12
The impact of concomitant therapies on the efficacy and safety of relugolix in advanced prostate cancer	12
Optimizing neoadjuvant treatment in HER2-positive breast cancer: the role of HER2, HR, PD-L1 expression and regimen selection	12
Finding the right tool for the specific task: navigating RWE tools and checklists	12
Clinical Effectiveness of Transcatheter Arterial Chemoembolization Sequential Microwave Ablation For Lack of Blood Supply in Hepatocellular Carcinoma	12
An investigator-initiated clinical study in patients with refractory or recurrent solid tumors: ‘R-ISV-FOLactis’ trial	12
Clinical characteristics of gastrointestinal stromal tumors with lymph node metastasis: a retrospective single-center study	12
Darolutamide plus androgen-deprivation therapy: propensity score matching of ARASEC and historic clinical trial patients	12
Prognostic Significance of the Systemic Inflammation Response Index in Gastrointestinal Malignancy Patients: A pooled Analysis of 10,091 Participants	11
Corrigendum	11
The prognostic indicator in breast cancer treated with CDK4/6 inhibitors: the prognostic nutritional index	11
Potential barriers to implementation of next-generation sequencing in cancer management: a U.S. Physician-based survey	11
Medicare characteristics, treatment, cost and survival in triple class exposed relapsed or refractory multiple myeloma	11
Gastric cancer in pregnancy: a review	11
The role of carboplatin in combination with paclitaxel in patients with castration-resistant prostate cancer	11
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer: A Plain Language Summary Of The DESTINY-Gastric01 Study	11
Plain language summary: comparing ivonescimab with pembrolizumab in people with PD-L1–positive non-small cell lung cancer in the HARMONi–2 study	11
Clinical outcomes of everolimus in patients with hormone receptor positive breast cancer: a real-world analysis	11
The prognostic value of systemic immune-inflammation index and prognostic nutritional index for colorectal cancer cases with liver metastasis post-transcatheter arterial chemoembolization	11
Impact of recurrence on employment, finances, and productivity for early-stage cancer patients and caregivers: US survey	11
Extension of lymph node dissection in the surgical treatment of esophageal and gastroesophageal junction cancer: seven questions and answers	10
Treatment efficacy score: a better surrogate for arm-level survival differences in neoadjuvant breast cancer trials?	10
Enzalutamide in biochemically recurrent prostate cancer: key findings from the EMBARK study	10
Disease landscape of advanced HER2-breast cancer patients by treatment line in three EU countries and USA	10
Pralsetinib in Patients with RET Fusion–Positive Non-Small-Cell Lung Cancer: A Plain Language Summary of the ARROW Study	10
Real-world treatment patterns in patients with non-metastatic non-small cell lung cancer in Greece: the ‘EVIDENCE’ study	10
The Correlation Between Skeletal Muscle Index and Anxiety in Patients with Lung Cancer on the First Day of Chemotherapy	10
Safety and efficacy of left colic artery preservation in laparoscopic anterior resection for lower rectal cancer	10
A phase I pharmacokinetic study of lenvatinib in Chinese patients with unresectable hepatocellular carcinoma	10
Mirvetuximab soravtansine for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer	10
Prognostic value of the glucose-to-lymphocyte ratio in surgically treated endometrial cancer: a retrospective cohort study	10
Methylation site APC 112043544 as a potential biomarker for post-transplant hepatocellular carcinoma recurrence	10
Treatment patterns in advanced/metastatic non-small-cell lung cancer in China: results from the CancerMPact ® survey 2021	9
A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed multiple myeloma	9
EGFR Exon 20 insertions in NSCLC: from biology to amivantamab, optimal treatment strategy and emerging therapeutics	9
A plain language summary of the results from the MAGNITUDE study assessing how effective and how safe niraparib and abiraterone acetate with prednisone is in patients with metastatic castration-resist	9
Evaluation of the prognostic effectiveness of liver metastasis volume by volumetric measurement in colorectal cancer	9
User-centered design of a COPD care pathway for patients with cancer: a mixed-methods clinical trial protocol	9
Neratinib as adjuvant therapy in patients with HER2 positive breast cancer: expert opinion	9
The JAVELIN Bladder Medley Trial: Avelumab-Based Combinations as First-Line Maintenance in Advanced Urothelial Carcinoma	9
Zolbetuximab plus chemotherapy for locally advanced unresectable or metastatic stomach or gastroesophageal junction cancers: a plain language summary	9
A real-world evaluation of the rapid diagnostic clinic roll out in South East London	9
Methylated ZNF582 as a triage marker for occult cervical cancer and advanced cervical intraepithelial neoplasia	9
E-VIRTUE: a study of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors—design and rationale	9
Enzalutamide in metastatic hormone-sensitive prostate cancer: A plain language summary of the ARCHES and ENZAMET follow-up studies	9

Long-term Results from a Clinical Study of Xevinapant Plus Chemoradiotherapy in People With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck: a Plain Language Summary	9
Real-world treatment patterns, healthcare resource utilization and costs among patients with peripheral T-cell lymphoma	9
Regorafenib in patients with metastatic colorectal cancer in Spain: from clinical trials to real-world evidence	9
Tumor mutational burden: why is it still a controversial agnostic immunotherapy biomarker?	9
Real-world outcomes after CAR T versus standard therapy in third-line or later relapsed or refractory follicular lymphoma in the United States	9
Impact of comorbidity on immune-related adverse events and survival in older cancer patients treated with immunotherapy	9
CaboCombo: a prospective, phase IV study of first-line cabozantinib + nivolumab for advanced renal cell carcinoma	9
Perspective on the Risk of Suicide Associated with Oral Cancer Diagnosis	9
Long-term outcomes of stage IIB–IV melanoma patients: nationwide data from Norway	9
Current practices for the management of advanced high-grade epithelial ovarian cancer in the UK: OC-NOW survey (2023)	8
Engineered exoASO-STAT6: a potent monotherapy for oral squamous cell carcinoma	8
Characterization of the immune environment in pregnancy-associated breast cancer	8
Clinical consensus on treatments for transplant-ineligible newly diagnosed multiple myeloma: double-blinded Delphi panel	8
Real-world Management Patterns in EGFR -mutant Advanced Non-Small-Cell Lung Cancer before First-Line Adoption of Osimertinib: The REFLECT Study in Greece	8
Matching-Adjusted Indirect Comparison of Amivantamab vs Mobocertinib in Platinum-Pretreated EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer	8
Tumor calcification is associated with better survival in metastatic colorectal cancer patients treated with bevacizumab plus chemotherapy	8
Research progress on the role of lipoxygenase and its inhibitors in prostate cancer	8
Fixed-duration ibrutinib-venetoclax for first-line treatment of patients with chronic lymphocytic leukemia: the REALITY-WW prospective real-world study cohort	8
Real-world effectiveness of first- and second-line anti-angiogenesis therapy in RCC: analysis of a UK-based population	8
Phase III MANIFEST-2: Pelabresib + Ruxolitinib vs Placebo + Ruxolitinib in JAK Inhibitor Treatment-Naive Myelofibrosis	8
Prognostic Value of GPC5 Polymorphism rs2352028 and Clinical Characteristics in Chinese Lung Cancer Patients	8
Nivolumab in unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma	8
Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non–small-cell lung cancer	8
Programmed cell death ligand 1 (PD-L1) inhibitors versus programmed cell death 1 (PD-1) inhibitors for the first-line therapy of extensive-stage small cell lung cancer: a propensity score-matched stud	8
Clinical outcomes for previously treated patients with advanced biliary tract cancer: a meta-analysis	8
Assessing the quality of patient-reported outcome measurements for gynecological cancers: a systematic review	8
NeoSCORE II: Three Vs Four Cycles of Neoadjuvant Sintilimab + Chemotherapy for Squamous Non-Small-Cell Lung Cancer	8
Chimeric antigen receptor T-cell treatment patterns in relapsed or refractory large B-cell lymphoma	8
LIVER-R study protocol: a global real-world study of durvalumab-based regimens in patients with hepatobiliary cancers	8
Plain language summary of IMerge, a Phase 3 study of imetelstat versus placebo in people with lower-risk myelodysplastic syndromes and anemia	8
Nab-paclitaxel vs paclitaxel liposome for advanced breast cancer: real-world efficacy and safety analysis	7
A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data	7
Cetuximab Every 2 Weeks Versus Standard Weekly Dosing Administration Schedule	7
Patient, caregiver experiences in metastatic castration-resistant prostate cancer: insights from a multi-national survey	7
Value of Biomarkers in Epithelial–Mesenchymal Transition Models Of Liver Cancer Under Different Interventions: A Meta-Analysis	7
Real-world drug utilization and treatment patterns in patients with tenosynovial giant cell tumors in the USA	7
How I treat Ph+ acute lymphoblastic leukemia	7
Prognostic implications of cancer-associated fibroblasts and desmoplastic reaction in stage III colon cancer risk groups	7
Hedgehog pathway inhibitor real-world treatment patterns in patients with basal cell carcinoma: a claims-based analysis	7
Genomic characteristics of PD-L1-Induced resistance to EGFR-TKIs in lung adenocarcinoma	7
Extended distal pancreatectomy in pancreatic cancer: is it justified? A systematic review of literature	7
NALIRIFOX in the upfront setting of metastatic pancreatic cancer: can FOLFIRINOX finally be dethroned?	7
A plain language summary of the AMPECT study: nab-sirolimus for advanced malignant perivascular epithelioid cell tumors	7
The Role of Surgery in Metastatic Cancer: The Case For a Pragmatic Tumor-Agnostic Randomized Trial	7
Treatment of advanced urothelial cancer with nivolumab plus chemotherapy versus chemotherapy alone (CheckMate 901 study): a plain language summary	7
Optimizing total neoadjuvant therapy in locally advanced rectal cancer: risk stratification should not be overlooked	7
Treatment patterns and outcomes in advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in China	7
A randomized phase II study comparing preoperative mFOLFOX6 versus FOLFOXIRI for locally advanced colon cancer: JCOG2006	7
Real-world treatment patterns and outcomes of patients with multiple myeloma initiating elranatamab: results from the ALTITUDE-1 and ALTITUDE-2 retrospective cohort studies	7
TUXEDO-4: phase II study of trastuzumab-deruxtecan in HER2-low breast cancer with new or progressing brain metastases	7
Correction	7
Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic phase: the ASC2ESCALATE Phase II trial	7
Real-world outcomes of patients with metastatic endocrine-responsive breast cancer receiving palbociclib-based combinations	7
Alpha radioligand therapy in neuroendocrine neoplasms: current landscape and spotlight on RYZ101	7
Prognostic role of prognostic nutritional index in patients with lymphoma-associated hemophagocytic lymphohistiocytosis	7
Plain language summary and patient perspective of the 2020 lung cancer screening recommendations by the US Preventive Services Task Force	7
A plain language summary of LocoMMotion – an observational study of treatments used for pretreated multiple myeloma	7
Addition of PI3K/AKT/mTOR inhibitors to fulvestrant for advanced HR+/HER2- breast cancer: a systematic review and meta-analysis	6
Plain language summary of the EVOKE-01 study of sacituzumab govitecan vs docetaxel in patients with non-small cell lung cancer	6
siRNA-Based Approaches for Castration-Resistant Prostate Cancer Therapy Targeting the Androgen Receptor Signaling Pathway	6
A genome-wide association study using HapMap cell lines reveals modulators of cellular response to cyclophosphamide	6
The first Middle East and North Africa expert consensus recommendations for management of advanced gastric cancer	6
The Implications from the Interplay of Neoadjuvant Chemoradiotherapy and the Immune Microenvironment in Rectal Cancer	6
Economic evaluation of Erdafitinib as a second-line treatment for advanced metastatic urothelial carcinoma: real-world data from the USA and prospective analysis from China	6
Prognostication for Surgically Treated Papillary Renal Cell Carcinoma: Which Model is the Optimal Choice?	6
MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer	6
The Power of Hope: Views of Ovarian Cancer Patients on How Maintenance Therapy Affects Their Lives (VOCAL)	6
Development and validation of a Cancer Patient Suicidal Ideation Scale	6
KRAS mutational analysis: a new supplementary diagnostic tool for extrahepatic biliary stenosis	6
Selpercatinib in the treatment of thyroid cancer	6
TEDOVA: vaccine OSE2101 +/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancer	6
Gemcitabine and cisplatin or oxaliplatin chemotherapy combined with atezolizumab plus bevacizumab for advanced biliary tract cancers: a single-arm trial	6
Post-marketing surveillance of tirabrutinib in 189 patients with r/r primary central nervous system lymphoma	6
Plain language summary of the management of certain side effects of teclistamab in people with multiple myeloma	6
Effect of Lateral Lymph Nodes Without Malignant Characteristics on the Prognosis of Patients with Rectal Cancer	6
Corrigendum	6
Real-world treatment of large B-cell lymphoma with chimeric antigen receptor T-cell therapy after loncastuximab tesirine: a plain language summary	6
Diagnostic journey and life impact of cholangiocarcinoma: results from surveys of patient and caregiver experiences	6
The Effects of Managing Cancer and Living Meaningfully (CALM) on Psychological Distress in Esophageal Cancer Patients	6
Corrigendum	6
DRP1: shedding light on the complex nexus of mitochondrial fission and breast cancer	6
Zanubrutinib in the treatment of Waldenström Macroglobulinemia	6
Real-world effectiveness of palbociclib plus hormone treatment and its impact on patient quality of life: a plain language summary of findings from POLARIS	6
Real-world treatment patterns and subsequent treatment effectiveness following frontline brigatinib in the ALTA-1L trial	6
Margetuximab in HER2-positive metastatic breast cancer	6
‘Perspectives of pulmonologists and thoracic surgeons on Oligometastatic disease: curability, treatment approaches, and disease trajectory’	6
Missed opportunities for earlier cancer diagnosis within specific pathways to emergency presentation	6
Cancer cytogenetics in the era of artificial intelligence: shaping the future of chromosome analysis	6
Integrating radium-223 therapy into the management of metastatic prostate cancer care: a plain language summary	6
ADJUBIL: Phase II Study of Adjuvant Immunotherapy with STRIDE Regimen With/Without Capecitabine in Biliary Tract Cancers	6
Prognostic Factors Affecting Infantile Medulloblastoma Outcomes in the Molecular Era: A 12-year Single-Center Experience from Egypt	6
Genetic variants in mitochondrial sirtuins associated with brain tumor risk: a case–control study	6
The impact of myelosuppression on quality of life of patients treated with chemotherapy	6
Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer: a plain language summary of the DESTINY-Breast04 study	6
Patterns of treatment in first and subsequent lines in RCC in Spain. A real-world descriptive cross-sectional study	6